Skip to main
OCGN

Ocugen, Inc. (OCGN) Stock Forecast & Price Target

Ocugen, Inc. (OCGN) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ocugen is uniquely positioned in the biotech industry due to their compelling clinical data across multiple large indications, two ongoing pivotal trials, and a strong pipeline of upcoming catalysts. This, along with their Modifier Gene Therapy Platform and Inhaled Mucosal Vaccine Platform, make them a promising company with a potential for significant growth and success in the future. Furthermore, they have a strong management team and have received positive feedback from the FDA, further adding to the company's potential. However, they still face risks common to the biotech industry and specific risks such as valuation and intellectual property concerns. Overall, the company has a positive outlook and strong potential for future success.

Bears say

Ocugen is a development stage company with no products currently on the market, leading to a need for additional capital. This could potentially result in dilution for stockholders or restrictive debt covenants. The success of Ocugen's development programs and regulatory processes is uncertain, and any negative results could lead to downward pressure on the stock. In addition, there is the potential for disagreement with regulatory authorities and the company's interpretations of data, as well as potential delays or limitations in obtaining approval for their products. The company also faces risks related to their intellectual property and potential infringement suits. Overall, there are significant risks and uncertainties surrounding Ocugen's future prospects, leading to a negative outlook on the stock.

Ocugen, Inc. (OCGN) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocugen, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocugen, Inc. (OCGN) Forecast

Analysts have given Ocugen, Inc. (OCGN) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Ocugen, Inc. (OCGN) has a Strong Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocugen, Inc. (OCGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.